Search
Palisade Bio Inc
PALIAdd to Watchlist
1.895USD
-0.065-3.32%
Close 07-31 16:00（ET）Quotes delayed by 15 min
328.93MMarket Cap
16.09P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Palisade Bio Inc is 8.67, ranking 74 out of 385 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 21.00 and a low of 6.00.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
10.400
Target Price
+448.81%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Palisade Bio Inc
PALI
10
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Palisade Bio Inc's price target?
Analysts forecast that Palisade Bio Inc's price target is USD 8.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 6.00.
How have Palisade Bio IncPALI's recent earnings per share performed?
The market expectation was USD -0.05, while Palisade Bio IncPALI's earnings per share (EPS) for the previous quarter was USD -0.16. EPS for the next quarter is expected at USD -0.05.
What is the analyst rating for Palisade Bio Inc?
Based on the ratings of Palisade Bio Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.